Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Promising hepatitis B treatment data presented by Vir Biotechnology
Vir Biotechnology's Phase 2 trial for chronic hepatitis B treatment showed significant HBsAg loss rates with tobevibart and elebsiran, with or without pegylated interferon alfa. The company aims for a functional cure by Q2 2025, with ongoing progress in hepatitis programs and T-cell engager trials. Financial stability and strategic restructuring support continued R&D efforts despite revenue challenges.
BioNTech to acquire Chinese oncology startup for almost US$1bn
BioNTech acquires Chinese oncology startup Biotheus for $950m to develop BNT327/PM8002 antibody, aiming to enhance oncology treatment portfolio and expand in China.
FDA Sets Date For Resubmitted Dupixent in Inflammatory Skin Disease
The FDA accepted the resubmission of Dupixent's sBLA for treating chronic spontaneous urticaria in adults and patients aged 12+; target action date is April 18, 2025. Dupixent, developed by Regeneron and Sanofi, inhibits IL-4 and IL-13 pathways and is approved for multiple indications. The resubmission includes data from Study C, showing Dupixent significantly reduced itch and urticaria activity in patients with uncontrolled CSU on antihistamines.
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the
FDA accepts Regeneron and Sanofi's resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria (CSU) in adults and pediatric patients aged 12 and older, with a decision expected by April 18, 2025. The resubmission includes pivotal data confirming Dupixent's significant reduction in itch and hive activity, supported by the LIBERTY-CUPID Phase 3 clinical program. If approved, Dupixent would be the first targeted therapy for CSU in a decade.
Conference on the future of Type 1 Diabetes screening organized as part of the ASSET
A conference on Type 1 Diabetes screening and treatment, organized by the Leading Healthcare Foundation and co-sponsored by Sanofi, will be held on November 26, 2024, in Stockholm. The event aims to explore precision and preventive medicine in Type 1 Diabetes care, featuring keynote lectures and panel discussions with stakeholders.
Glioblastoma Clinical Trials 2024: EMA, PDMA, FDA Approvals
DelveInsight's 'Glioblastoma Pipeline Insight, 2024' report details 190+ companies developing 200+ therapies, including Enzastaurin, Marizomib, VT1021, and ONC201, with insights on mechanism of action, route of administration, and market dynamics.
Related Clinical Trials:
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
FDA accepts Dupixent sBLA for chronic spontaneous urticaria treatment, with pivotal data showing significant itch and hive reduction. Decision expected by April 18, 2025, potentially marking the first targeted therapy for CSU in a decade.
Press Release: Dupixent sBLA accepted for FDA review for
FDA accepts Dupixent sBLA for chronic spontaneous urticaria, with a decision expected by April 18, 2025. New data confirm Dupixent significantly reduces itch and hive activity, potentially offering the first targeted therapy for CSU in a decade.
© Copyright 2024. All Rights Reserved by MedPath